BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Lunit and Microsoft collaborate to advance AI-driven cancer diagnosis

July 3, 2025 | News

Marking a significant milestone in Lunit's mission to expand access to AI tools, particularly in the US market



South Korea-based Lunit, a leading provider of artificial intelligence (AI) for cancer diagnostics and therapeutics, has announced a collaboration with Microsoft to accelerate the delivery of AI-powered healthcare solutions.

In conjunction with their recent acquisition of Volpara, a Microsoft Industry Health Certified Partner, this collaboration will give health professionals globally access to tools that will assist in the detection of cancer.

By joining forces with Microsoft, Lunit is poised to deliver scalable technologies that not only streamline radiology workflows but also drive measurable improvements in diagnostic consistency and patient care across diverse healthcare settings.

This marks a significant milestone in Lunit's mission to expand access to AI tools, particularly in the US market, by leveraging Microsoft Azure's global cloud infrastructure and deep expertise in healthcare-focused AI technologies.

Key highlights of the collaboration include:

- **Co-Development of AI Model Customisation Service on Azure:** Lunit and Microsoft collaborate to develop a service that allows fine-tuning of AI models using site-specific clinical data from each customer. This approach helps mitigate cross-site model performance variability, one of the key challenges in deploying AI in real-world clinical environments, and ensures more reliable, tailored outcomes in diverse clinical settings.

- **Leveraging Microsoft's AI Platform for Innovative Workflow Solutions:** Moving beyond point solutions, Lunit will leverage Microsoft's agentic AI frameworks, designed to support intelligent task automation, to develop end-to-end workflow automation tools. These solutions aim to simplify clinical decision-making and enhance operational efficiency across the care continuum.